EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression

Maria Gałuszko-Węgielnik iD, Zuzanna Chmielewska iD, Katarzyna Jakuszkowiak-Wojten, Mariusz S Wiglusz, Wiesław J Cubała iD

Brain Sciences · 13.01.2023 · 13 (1) · 142

DOI: 10.3390/brainsci13010142 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain Sciences, online erschienen am 13.01.2023. Verfasst von Maria Gałuszko-Węgielnik und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Smoluchowskiego 17, 80-214 Gdańsk, Poland. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Gdansk, Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psychotic treatment-resistant depression is a complex and challenging manifestation of mood disorders in the clinical setting. Psychotic depression is a subtype of major depressive disorder characterized by mood-consistent hallucinations and/or delusions. Psychotic depression is often underdiagnosed and undertreated. Ketamine appears to have rapid and potent antidepressant effects in clinical studies, and the Federal Drug Agency approved the use of ketamine enantiomer esketamine-nasal spray for treatment-resistant depression pharmacotherapy in 2019. This study aimed to assess the usage of ketamine for major depressive disorder with psychotic features as an add-on treatment to the standard of care. Here we present four inpatients suffering from treatment-resistant depression with psychotic features, including one with severe suicidal crisis, all treated with 0.5 mg/kg intravenous infusion of ketamine. Subsequent monitoring revealed no exacerbation of psychotic symptoms in short and long-term observation, while stable remission was observed in all cases with imminent antisuicidal effect. Results suggest ketamine may benefit individuals with treatment-resistant depression with psychotic features.

Schlagwörter

Stichwörter der Autor:innen

esketamineketaminepsychotic depressiontreatment-resistant depression

Autor:innen und Institutionen

  • Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Smoluchowskiego 17, 80-214 Gdańsk, Poland.

ORCID-Profile: Maria Gałuszko-Węgielnik, Zuzanna Chmielewska, Wiesław J Cubała

Förderung

  • Medical University of Gdansk, Poland

Zitieren

APA

Gałuszko-Węgielnik, M., Chmielewska, Z., Jakuszkowiak-Wojten, K., Wiglusz, M. S., & Cubała, W. J. (2023). Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression. Brain Sciences, 13(1), 142. https://doi.org/10.3390/brainsci13010142

Vancouver

Gałuszko-Węgielnik M, Chmielewska Z, Jakuszkowiak-Wojten K, Wiglusz MS, Cubała WJ. Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression. Brain Sciences. 2023;13(1):142. doi:10.3390/brainsci13010142

BibTeX
@article{GauszkoWgielnik2023,
  author = {Gałuszko-Węgielnik, Maria and Chmielewska, Zuzanna and Jakuszkowiak-Wojten, Katarzyna and Wiglusz, Mariusz S and Cubała, Wiesław J},
  title = {Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression},
  journal = {Brain Sciences},
  year = {2023},
  volume = {13},
  number = {1},
  pages = {142},
  doi = {10.3390/brainsci13010142}
}
Kostenlos starten →